What is CorMedix's undistributed earnings?

CorMedix (CRMD) reported undistributed earnings of $247K in Q4 2025.

What does undistributed earnings mean?

The portion of net income that has not been distributed to shareholders as dividends and is instead retained for reinvestment in the business. This reflects the company's internal capital allocation strategy and growth reinvestment capacity.

CorMedix CRMD Undistributed Earnings

Undistributed Earnings at other companies

Piper SandlerPIPR

$0—

IDT CorporationIDT

$304M+2.4%

WEXWEX

$370.1M+10.1%

Minerals TechnologiesMTX

$516.3M—

KadantKAI

$150.89M-49.0%

Crane NXT, Inc.CXT

$679.6M+121%

Other financials

Income statement

See full

Revenue$127.4M+226%

Gross profit$115.4M+207%

Operating income$63.7M+216%

Net income$38.6M+87.0%

EPS (diluted)$0.43+43.3%

Balance sheet

See full

Cash & equivalents$179.1M+170%

Total debt$4.3M+729%

Total equity$437.0M+280%

Total assets$815.6M+445%

Cash flow

See full

Operating cash flow$42.4M+115%

CapEx$729.0K+7,190%

Free cash flow$41.7M+111%

Valuation

See full

Market cap$605.65M-34.4%

P/E3.4×—

P/S1.5×-9.6×

Profitability

See full

Gross margin91.9%-3.5pp

Operating margin48.4%—

Net margin45.2%—

FCF margin48.7%+38.8pp

Returns & leverage

See full

Return on equity65.6%—

Debt / equity0×0.0×

Current ratio3×-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:UndistributedEarnings.

The official record: CorMedix’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's undistributed earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CorMedix's undistributed earnings?: CorMedix (CRMD) reported undistributed earnings of $247K in Q4 2025.
What does undistributed earnings mean?: The portion of net income that has not been distributed to shareholders as dividends and is instead retained for reinvestment in the business. This reflects the company's internal capital allocation strategy and growth reinvestment capacity.